NCT07236021 e-Motion : Promoting Emotion Regulation in Chronic Cancer
| NCT ID | NCT07236021 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Université Libre de Bruxelles |
| Condition | Metastatic Cancers |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-11-20 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-11-20 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The present study aimed to pilot evaluate two interventions: a Guided Self-Help Intervention alone, and a combined Group and Guided Self-Help Intervention, designed to support individuals living with chronic cancer and recently diagnosed. The primary aim of this pilot study is to assess the feasibility, acceptability and tolerability of the interventions. The secondary aim of the pilot study is to assess the interventions preliminary efficacy and differences on psychological symptoms.
Eligibility Criteria
Inclusion Criteria: * Having received a diagnosis of chronic cancer (metastatic breast cancer, metastatic melanoma, metastatic colorectal, metastatic ovarian, metastatic uterine, metastatic endometrial, metastatic prostate, metastatic bladder, metastatic kidney or metastatic testicular cancer, symptomatic multiple myeloma, metastatic non-small cell lung, metastatic mesothelioma or metastatic thymoma) in the past 12 months, * Having completed at least one active treatment session (e.g., chemotherapy, surgery, radiotherapy, immunotherapy, target therapy). Exclusion Criteria: * Having less than one year of life expectancy * Having more than one treatment line (for triple negative breast cancer, melanoma, gynecological cancer, colorectal cancer, bladder cancer, kidney cancer, non-small cell lung, mesothelioma and thymoma) or two treatment lines (for other breast cancers and testicular cancer) or three treatment lines (for prostate cancer and multiple myeloma), * Having a diagnosis of oligometastatic cancer, * Age \< 18 years, * Non-fluency in French, * Inability to follow the online intervention, * Severe cognitive impairment, and severe and/or acute psychiatric disorder.
Contact & Investigator
Florence Lewis, PhD
PRINCIPAL INVESTIGATOR
Université Libre de Bruxelles
Frequently Asked Questions
Who can join the NCT07236021 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastatic Cancers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07236021 currently recruiting?
Yes, NCT07236021 is actively recruiting participants. Contact the research team at florence.lewis@hubruxelles.be for enrollment information.
Where is the NCT07236021 trial being conducted?
This trial is being conducted at Brussels, Belgium, Brussels, Belgium.
Who is sponsoring the NCT07236021 clinical trial?
NCT07236021 is sponsored by Université Libre de Bruxelles. The principal investigator is Florence Lewis, PhD at Université Libre de Bruxelles. The trial plans to enroll 30 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.